3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Fatigue
14
Neoplasms
6
Brain Neoplasms
5
Prostatic Neoplasms
4
Depression
4
Sleep Wake Disorders
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Central Nervous System Neoplasms
2
Breast Neoplasms
2
Asthenia
2
Recurrence
1
Oligodendroglioma
1
Neurotoxicity Syndromes
1
Neurofibromatosis 1
1
Neuroectodermal Tumors, Primitive
1
Neoplasm Metastasis
1
Meningioma
1
Hematologic Neoplasms
1
Gliosarcoma
1
Glioma, Subependymal
1
Glioma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Ependymoma
1
Cognitive Dysfunction
1
Astrocytoma
1
Anxiety Disorders
1
Interventions
Exercise
6
Transcranial Direct Current Stimulation
4
Neuropsychological Tests
4
Walking
3
Memantine
3
Tablets
2
Standard of Care
2
Patient Reported Outcome Measures
2
Methods
2
Electroencephalography
2
Donepezil
2
Cognitive Behavioral Therapy
2
mazdutide
1
lime
1
enzalutamide
1
blueberry extract
1
beta Carotene
1
acetaminophen, aspirin, caffeine drug combination
1
Vitamin E
1
Vitamin D
1
Ultraviolet Therapy
1
Transcranial Magnetic Stimulation
1
Time
1
Therapeutics
1
Tai Ji
1
Surveys and Questionnaires
1
Sugars
1
Sodium Chloride
1
Sirolimus
1
Silymarin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Cognitive Dysfunction
×
Methylphenidate
×
Clear all
NCT02970500
2023-03-23
CogMet
CHU de Quebec-Universite Laval
Phase 2
Terminated
20 enrolled